KLRB1 and myeloid sarcoma: Given that RRMS patients included in this study had no evidence of disease activity at the time of blood sampling, this finding suggests that increased CD3+CD161+ cell levels may serve as a potential biomarker for differentiating healthy individuals not only from relapsing MS patients but also from RRMS patients with no current evidence of disease activity.